Argenx Appoints Karen Massey as New CEO in Leadership Transition
Argenx announced on January 5, 2026, that COO Karen Massey will become the new CEO, succeeding founder Tim Van Hauwermeiren, who transitions to Non-Executive Director and Chairman.12
The change supports argenx's Vision 2030 growth strategy amid expansion in treatments for severe autoimmune diseases like generalized myasthenia gravis using Vyvgart.12
Karen Massey, with extensive experience in pharmaceutical commercial operations and product launches, joined argenx three years ago and accelerated Vyvgart's launch.12
Tim Van Hauwermeiren will focus on long-term strategy, board governance, and partnerships as Chairman.12
The transition ensures continuity for patients and pipeline advancement in immunology and rare diseases.1
Sources:
1. https://entrepreneurloop.com/argenx-ceo-steps-down-van-hauwermeiren-chairman/